Targets, trials, and travails in pancreas cancer.
Pancreas cancer is a highly aggressive and rapidly fatal disease. The current standard of care for advanced disease improves survival modestly at best and provides palliation for a minority of patients. The need for new therapies is undisputed. This article describes new therapeutic strategies currently under investigation and discusses possible reasons that others have failed. New potential targets in the treatment of this formidable disease are suggested based on recent findings.
Izeradjene
Kamel
K
Clinical Research and Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.
Hingorani
Sunil R
SR
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004815:Epidermal Growth Factor / Q000235:genetics; D066246:ErbB Receptors / Q000187:drug effects; D016147:Genes, Tumor Suppressor / Q000502:physiology; D006801:Humans; D007167:Immunotherapy; D008264:Macrophages / Q000276:immunology; D061965:Matrix Metalloproteinase Inhibitors; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras); D012697:Serine Endopeptidases / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D018631:ras Proteins / Q000235:genetics / Q000378:metabolism
D000970:Antineoplastic Agents; C117307:KRAS protein, human; D061965:Matrix Metalloproteinase Inhibitors; D011518:Proto-Oncogene Proteins; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D012697:Serine Endopeptidases; C485596:ST14 protein, human; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins